Holen Sie sich die Stockscreener-App
536.12
0.62%
3.30
Handel nachbörslich:
536.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - TradingView
UBS raises United Therapeutics stock price target to $705 on catalysts - Investing.com Nigeria
Cantor Fitzgerald raises United Therapeutics stock price target to $625 - Investing.com Nigeria
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
Inhaled IPF drug from United Therapeutics slows lung scarring in trial - Stock Titan
United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade) - Seeking Alpha
Capital Fund Management S.A. Purchases 20,410 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp (UTHR) Shares Up 3.04% on Mar 10 - GuruFocus
United Therapeutics (NASDAQ:UTHR) Sets New 1-Year HighHere's What Happened - MarketBeat
United Therapeutics stock hits all-time high at 537.83 USD - Investing.com
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains? - Yahoo Finance
Grantham Mayo Van Otterloo & Co. LLC Acquires 6,079 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Insider Sell: Judy Olian Sells 200 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics Corp (UTHR) Shares Up 8.91% on Mar 9 - GuruFocus
United Therapeutics Launches $1.5 Billion Accelerated Share Repurchases With Citi Under $2 Billion Buyback - TradingView
United Therapeutics stock jumps 9% on $2B buyback program - Investing.com
United Therapeutics stock buyback signals franchise confidence, TD Cowen says - Investing.com Nigeria
United Therapeutics (NASDAQ:UTHR) Shares Gap UpStill a Buy? - MarketBeat
United Therapeutics authorizes $2 billion buyback program - Investing.com
United Therapeutics sends $1.5B upfront for stock, $500M left - Stock Titan
First Trust Advisors LP Trims Stake in United Therapeutics Corporation $UTHR - MarketBeat
Rhenman & Partners Asset Management AB Buys Shares of 8,000 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Shares Positive Study Results for its Bioengineered Liver - Medical Product Outsourcing
Ray Kurzweil Sells 4,910 Shares of United Therapeutics Corp - GuruFocus
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $978,840.00 in Stock - MarketBeat
United Therapeutics (UTHR) Receives Increased Price Target from UBS | UTHR Stock News - GuruFocus
Fisher Asset Management LLC Buys 4,987 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate - ChartMill
United Therapeutics Shares Drop 1.69% as Revenue Shortfall Outweighs Profit Surpass; Trading Volume Places 493rd - Bitget
AustralianSuper Pty Ltd Cuts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics pill shows late-stage success in rare lung disease PAH - IndiaMedToday
TD Cowen reiterates United Therapeutics stock Buy on ralinepag trial success - Investing.com India
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics CEO to give update at Leerink healthcare conference - Stock Titan
Leerink raises United Therapeutics stock price target on trial data - Investing.com South Africa
Leerink raises United Therapeutics stock price target on trial data By Investing.com - Investing.com India
Jefferies raises United Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Jefferies raises United Therapeutics stock price target on trial data - Investing.com South Africa
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics Hits Day High with 13% Surge in Strong Intraday Performance - Markets Mojo
H.C. Wainwright reiterates Buy on United Therapeutics stock - Investing.com South Africa
H.C. Wainwright reiterates Buy on United Therapeutics stock By Investing.com - Investing.com UK
United Therapeutics (UTHR): Investor Outlook With A 13% Upside Potential - DirectorsTalk Interviews
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - marketscreener.com
United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening - Benzinga
United Therapeutics reports positive phase 3 trial for ralinepag By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Reports Positive Phase 3 Results for Ralinepag - GuruFocus
United Therapeutics reports positive phase 3 trial for ralinepag - Investing.com
United Therapeutics: Ralinepag cuts risk of clinical worsening by 55% in pivotal PAH trial - TradingView
Ralinepag cuts PAH clinical worsening by 55% in UTHR (NASDAQ: UTHR) phase 3 trial - Stock Titan
Once-daily PAH drug by United Therapeutics slows progressive disease - Stock Titan
United Therapeutics Corporation $UTHR Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
2.10%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):